Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Recruiting · NCT04969731 · Registry updated 2021-11-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic ductal adenocarcinoma, pancreatic neoplasm | Recruiting | Phase 3 | 2021-11-22 | NCT04969731 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| GC Cell Corporation | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Seoul National University Hospital | Seoul | South Korea | 1 |